Search

Displaying results 5421 - 5430 of 10000 in total
  1. Drug

    Enarodustat

    go.drugbank.com/drugs/DB14985
    Investigational

    Enarodustat is under investigation in clinical trial NCT02581124 (Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease).

  2. Drug

    Firuglipel

    go.drugbank.com/drugs/DB19506
    Investigational

    Firuglipel is under investigation in clinical trial NCT02647320 (12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin). … Firuglipel has a monoisotopic molecular weight of 467.19 Da.

  3. Drug

    Larazotide

    go.drugbank.com/drugs/DB05645
    Investigational

    An octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.

  4. Drug

    Terevalefim

    go.drugbank.com/drugs/DB16397
    Investigational

    Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).

  5. Drug

    Sulesomab

    go.drugbank.com/drugs/DB13976
    Approved

    Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.

  6. Drug

    Betulinic Acid

    go.drugbank.com/drugs/DB12480
    ApprovedWithdrawn

    Betulinic Acid has been used in trials studying the treatment of Dysplastic Nevus Syndrome.

  7. Drug

    5-O-phosphono-alpha-D-ribofuranosyl diphosphate

    go.drugbank.com/drugs/DB01632
    ApprovedWithdrawn

    The key substance in the biosynthesis of histidine, tryptophan, and purine and pyrimidine nucleotides.

    Synonyms: 5-O-phosphono-α-D-ribofuranosyl diphosphate, 5-O-phosphono-alpha-D-ribofuranosyl diphosphate
  8. Drug

    NCX 1022

    go.drugbank.com/drugs/DB05410
    Experimental

    NCX is an NO-releasing derivative of hydrocortisone.

  9. Drug

    NNZ-2591

    go.drugbank.com/drugs/DB15601
    Investigational

    NNZ-2591 (cyclo-L-glycyl-L-2-allylproline)[A189390] is an investigational synthetic analog of cyclic glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been … [L11106] It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of Angelman, Phelan-McDermid, and Pitt Hopkins Syndromes.

  10. Drug

    Balipodect

    go.drugbank.com/drugs/DB14774
    Investigational

    Balipodect is under investigation in clinical trial NCT01892189 (Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults).